Novartis halted CAR-T trials after three patient deaths linked to a severe autoimmune reaction following dosing with zola-cel (rapcabtagene autoleucel). The company said it is investigating several clinical trial programs, as the immune event aligns with IEC-HS, a complication associated with CAR-T therapies. Bristol Myers Squibb followed with a pause of its zola-cel trials, describing reversible inflammatory events that prompted a voluntary pause while the company reviews clinical data. Both programs target CD19, and the reports point to heightened safety monitoring focus around systemic inflammatory cascades and autoimmune phenotypes. For the cell therapy ecosystem, the actions are a reminder that benefit-risk assessments can rapidly shift across indications, particularly in autoimmune disease where tolerability thresholds and monitoring expectations may differ from oncology settings. Trial pauses can also influence timelines for competing CAR-T and bispecific approaches seeking to expand into earlier-line or broader patient groups.